Epiminder Extends Stratus Partnership to Support US Minder Launch
EPI: $0.270 -1.82% · MC: $61M
Epiminder has signed a five-year rolling partnership with US neurodiagnostics provider Stratus Neuro, extending an existing agreement supporting its DETECT reimbursement study. Minder’s long-term brain monitoring data will be integrated into the StratusEEG platform to support the study and the commercial launch of the next-generation system. Earlier this month, Epiminder said the US Medicare payment rate for the Minder implant procedure would rise by approximately 13% in 2027.

Comments